Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 205 participants.
Also called NCT02452736
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 205 participants
- Sponsor
- Registry
-
NCT02452736
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT02452736. Allocation not applicable; no masking; primary purpose treatment. Start 2015-05 (registry gives no type); primary completion 2015-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
- Condition
- Ischemic Heart Disease
- Condition
- Cardiovascular Diseases
- Condition
- Arteriosclerosis
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System
- Lead sponsor
- Medtronic Vascular
Record details
- Record id
cardio:ct-nct02452736- Content hash
3e4d5f9e679909cc982f940d9b4ecf91b3e79dffb64f766da8daa5232177f858